BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 25
• 26
• 27
• 28

• 

  Drug Development

  Madrigal’s Cholesterol Drug Succeeds in Mid-Stage Trial

  MGL-3196 was well-tolerated with primarily mild and some moderate AEs.

  February 8, 2018

   · 

  9 min read
• Lipocine Announces $10M Loan and Security Agreement With Silicon Valley Bank

  For further details on the terms of the loan, refer to the Form 8-K filed by Lipocine with the SEC on January 5, 2018.

  February 8, 2018

   · 

  3 min read
• Business

  AnaBios Announces Agreement to Develop Atrial Fibrillation Treatment

  The program will focus on compounds designed to modulate a novel cardiac ion channel target.

  February 8, 2018

   · 

  1 min read
• Biotech Beach

  Epic Sciences to Present Single Cell PSMA Analysis to Provide Insight Into Tumor Heterogeneity and Links to Response With Anti-PSMA Therapy

  Within patient samples, single cell analysis showed that PSMA expression was heterogeneous from cell to cell demonstrating the complexity of target expression.

  February 8, 2018

   · 

  3 min read
• Business

  MEI Pharma Reports Second Quarter Fiscal Year 2018 Results

  MEI Pharma today reported results for its second quarter ended December 31, 2017.

  February 8, 2018

   · 

  14 min read
• Business

  BioGX and Launch Diagnostics Announce Distribution Partnership for U.K. and Ireland

  BioGX continues to expand its global presence with the announcement of a distribution partnership between BioGX’s Amsterdam-based European subsidiary, BioGX B.V., and U.K.-based distributor, Launch Diagnostics.

  February 8, 2018

   · 

  3 min read
• 

  FDA

  Janssen Zytiga Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer

  The approval is based on Phase 3 data from the pivotal LATITUDE clinical trial.

  February 8, 2018

   · 

  12 min read
• Business

  Perrigo to Release Fourth Quarter and Calendar Year 2017 Financial Results On February 27, 2018

  Perrigo today announced that it will release its fourth quarter and calendar year 2017 financial results on Tuesday, February 27, 2018.

  February 8, 2018

   · 

  4 min read
• Business

  Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Period Activity

  At December 31, 2017, Alnylam had cash, cash equivalents and fixed income marketable securities, and restricted investments of $1.73 billion, as compared to $1.09 billion at December 31, 2016.

  February 8, 2018

   · 

  22 min read
• Business

  Aurinia Enhances Commercial and Business Development Expertise with the Appointment of Joseph P. Hagan to its Board of Directors

  Mr. Hagan is currently the President and Chief Executive Officer of Regulus Therapeutics.

  February 8, 2018

   · 

  4 min read